Cancer Drug Prices Slashed Up To 86% In A Year: Regulator
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.06-03-2017
06-03-2017
Investor Presentation
Natco Pharma Ltd has submitted to BSE a copy of Investor Presentation for the quarter ended December 31, 2016.16-02-2017
Results Press Release for December 31, 2016
Natco Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 201614-02-2017
Fixes Record Date for Interim Dividend
Natco Pharma Ltd has informed BSE that the Company has fixed February 27, 2017 as the Record Date for the purpose of payment of Interim Dividend.The said interim dividend will be paid from March 03, 2017 onwards.14-02-2017
Announces Q3 results (Standalone & Consolidated), Limited Review Report (Standalone & Consolidated) & Results Press Release for the Quarter ended December 31, 2016
Natco Pharma Ltd has announced the following results for the quarter ended December 31, 2016:"The Unaudited Standalone results for the Quarter ended December 31, 2016The Company has posted a net profit of Rs. 1970.70 million for the quarter ended December 31, 2016 where as the same was at Rs. 433.20 million for the quarter ended December 31, 2015. Total Income is Rs. 6727.60 million for the quarter ended December 31, 2016 where as...14-02-2017
Board declares Second Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2017, inter alia, has declared second interim dividend of Rs.6/- (Rupees six only) on each equity share of Rs.2/- (Rupees two only) each for the year 2016-17.14-02-2017
Earnings Call for the quarter ended December 31, 2016
Natco Pharma Ltd has informed BSE regarding "Earnings Call for the quarter ended December 31, 2016".09-02-2017
Q3 results on Feb 14, 2017
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on February 14, 2017, inter alia, to consider the following items of business:1. The unaudited financial Results for the quarter ended December 31, 2016 (Q3) and related matters.2. To consider second Interim Dividend, if any, for the financial year 2016-17 and related matters etc....02-02-2017
NATCO's partner Mylan Wins U.S. District Court Ruling Related to Copaxone 40 mg/mL Patents
Natco Pharma Ltd has submitted to BSE a copy of Press Release dated January 31, 2017 titled ''NATCO's partner Mylan Wins U.S. District Court Ruling Related to Copaxone 40 mg/mL Patents".31-01-2017
USFDA raises issues over Natco Pharma's formulations plant
The US Food and Drug Administration (USFDA) has raised some issues after inspection of its Kothur formulations facility. The inspection was conducted in the Kothur plant near here during January...25-01-2017